SGLT-2 inhibitors
Need of the hour: pharmacovigilance study of SGLT-2 inhibitors
... of SGLT-2 inhibitors (Urinary tract infections; genital infections; symptoms of hypoglycaemia-dizziness, fainting; increased urine frequency/ volume; symptoms suggestive of DVT-Pain in the legs, ...
5
Prospective Study on Prescribing Pattern and Short-Term Outcomes of SGLT-2 Inhibitors in a Tertiary Care Hospital
... Historically, the aim of glucose-lowering therapy in diabetes is to reduce microvascular complications. Whereas, interventional studies focused on intensive glucose reduction in T2DM have only had a minor or no effect in ...
99
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control
... on SGLT-1, which can result in GI side effects, including ...Other SGLT-2 inhibitors, such as sergliflozin, did not reach advanced stages of clinical development for reasons related to their ...
8
SGLT-2 inhibitors and their potential in the treatment of diabetes
... co-transporter 2 (SGLT-2) inhibitors have rested tantalizingly on the horizon, promising a more physiological approach to glucose ...Consequently, SGLT-2 inhibitors ...
15
<p>Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors</p>
... urogenital infections developed during the study or other side effects that required discontinuation of treatment with dapagli fl ozin, or the patient ’ s refusal to take part in the study. We initially recruited 68 ...
8
<p>SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions</p>
... Peptidase-4 inhibitors, addition of Ipragli fl ozin resulted in a signi fi cant reduction of ALT levels and Fibrosis Index-4 (FIB-4) in approximately half of the patients irrespective of their initial treatment; ...
12
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
... cotransporter 2 (SGLT-2) inhibi- tors are now widely used for antihyperglycemic ...therapy. SGLT-2 inhibitors decrease reabsorption of glucose in the renal tubular ...initiating ...
8
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
... when SGLT-2 inhibitors are associated with insulin therapy, may not be sufficient to block gluconeogenesis in the liver, with a net consumption of oxaloacetate (for gluconeogenesis) impeding the ...
14
Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
... type 2 diabetes (T2D) treated by SGLT-2 ...this SGLT-2 inhibitors effect is unique because, at vari- ance with other components of cardiorenal protection, MACE prevention does ...
6
REVIEW ON SODIUM GLUCOSE CO-TRANSPORTER-2 (SGLT2) INHIBITORS: A NEW CLASS OF ANTI-DIABETIC DRUG Saerah Simon, Sidhi Sunil, Mrs. Renuka R*, Dr. Elessy AbrahamDOWNLOAD/VIEW
... SGLT-2 inhibitors have a novel mechanism of action that is independent of insulin secretion and ...SGLT2 inhibitors (including dapagliflozin, canagliflozin, empagliflozin) for the treatment of ...
5
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
... Despite unchanged levels of LDL-C, dapagliflozin markedly decreased the levels of potent atherogenic sd LDL-C and increased levels of the less atherogenic lb LDL-C. Lb LDL-C levels were further elevated in the subset of ...
13
<p>The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers</p>
... Furthermore, SGLT-2 inhibitors have been reported to have renoprotective effects, such as a reduction in the rate of decline in renal function and a reduction of proteinuria in patients with early- ...
11
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
... of 2 years in patients at lower risk. The results of the SGLT-2 inhibitors may be limited by the relatively low number of patients and events in the SGLT-2 inhibitor ...
11
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
... more, SGLT-2 inhibitors can shift metabolism from car- bohydrate to lipid [33, 42] and increase ketone body level in both animal and clinical studies ...of SGLT-2 inhibi- tors ...
17
Practical combination therapy based on pathophysiology of type 2 diabetes
... and SGLT-2 inhibitors are appropriate for use in combination with one another or in combination with more traditional agents (eg, metformin, TZDs, insulin) to reduce A1C without increasing the risk ...
15
The effect of dapagliflozin treatment on epicardial adipose tissue volume
... by SGLT-2 inhibitors is also typically asso- ciated with a net loss of ~ 200–300 kcal, leading to weight reductions of ~ 2–3 kg over 24–52 ...an SGLT-2 inhibitor even improved ...
9
Prolonged diabetic ketoacidosis associated with canagliflozin
... to SGLT-2 ...glucosuria. SGLT-2 inhibitors are recognised to cause glucosuria for several days after discontinuation (8, ...of SGLT-2 inhibitors may also be ...
5
SGLT 2 receptor inhibitors for treating patients with type 2 diabetes mellitus : a systematic review and network meta analysis
... different SGLT-2 inhibitors, the distribution of treatment effect modi fi ers cannot only vary across trials for a particular comparison (as with standard pairwise meta-analysis, causing ...
22
<p>Canagliflozin review – safety and efficacy profile in patients with T2DM</p>
... Renal: In June 2016, the FDA warned about the possibility of acute renal failure (ARF) with canagliflozin based on a review of the data reported from March 2013 to October 2015. As a result, a retrospective study by ...
7
REVIEW ONPHARMACOKINETICS OF EMPAGLIFLOZIN, AN INHIBITOR OF THE SODIUM GLUCOSE CO TRANSPORTER 2 (SGLT 2)
... kidneys. SGLT-2 accounts for about 90% of glucose reabsorption into the ...Blocking SGLT-2 reduces blood glucose by blocking glucose reabsorption in the kidney and thereby excreting glucose ...
7